The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
BVd vs DVd in patients with R/R MM: Results from the DREAMM-7 trial
|
Belantamab mafodotin, a BCMA-targeted antibody-drug conjugate, has demonstrated efficacy in patients with multiple myeloma (MM). The phase III DREAMM-7 trial (NCT04246047) is assessing the safety and efficacy of belantamab mafodotin in combination with bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in patients with relapsed/refractory (R/R) MM with ≥1 prior line of therapy.1 Results from this trial were presented by Mateos1 during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. |
| Key learnings: |
|
The DREAMM-7 study met its primary endpoint of progression-free survival (PFS): median PFS was 36.6 months vs 13.4 months in the BVd and DVd arms, respectively (p < 0.00001); this benefit was sustained across prespecified subgroups, including patients with lenalidomide-refractory or high-risk cytogenetic MM. |
|
BVd also improved overall survival (OS) vs DVd, with 12-month and 18-month OS rates of 87% vs 81% and 84% vs 73%, respectively. |
|
BVd was associated with a higher ≥complete response (CR) rate (34.6% vs 17.1%) and a higher ≥CR with measurable residual disease-negativity rate (24.7% vs 9.6%) when compared with DVd. |
|
The safety profile of BVd was consistent with that of the individual agents, and ocular adverse events were generally manageable, leading to discontinuation in 9% of patients. |
|
These results suggest that BVd could be a new standard of care for patients with R/R MM. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
